Jazz Pharmaceuticals To Present New Analysis Of Defibrotide Data In...

Posters Include an Epidemiological Measure of the Effectiveness Analysis of Defibrotide from a Phase 3 Trial in Severe Hepatic VOD, as well as Updates from an International Compassionate Use Program and a U.S. Treatment IND Study Posters Include an Epidemiological Measure of the Effectiveness Analysis of Defibrotide from a Phase 3 Trial in Severe Hepatic VOD, as well as Updates from an International Compassionate Use Program and a U.S. Treatment IND Study /PRNewswire/ -- Jazz Pharmaceuticals plc announced today that researchers will present the results of a number needed to treat analysis from a historically controlled Phase 3 clinical trial evaluating the use of defibrotide for the treatment of severe hepatic veno-occlusive disease in patients undergoing hematopoietic stem-cell transplantation therapy.

http://ift.tt/11Qzcay